Earlier this summer J. Wiley & Sons published a new book called “Pharmaceutical Anti-Counterfeiting, Combating the Real Danger from Fake Drugs” by Mark Davison, CEO of Blue Sphere Health, a pharmaceutical consultancy. I pre-ordered it on Amazon.com in the spring and it was finally delivered in July. You may have noticed the image and link I added to the left margin under “RxTrace Recommends” shortly after I started reading it. The hardbound book is 400 pages, including the main text, notes, references, glossary and index, but it took me until now to finish reading it. I’ve been so busy lately that I could only read a few pages at a time, that is until my vacation when I finally had time to sit down and read the whole book.
The book is broken up into five parts. Part 1, General Themes, provides an in-depth examination of the problem of drug counterfeiting around the world including its formal definition, the origins, costs, risks, and the contrast (and controversy) between intellectual property and anti-counterfeiting. In the last chapter of Part 1, Davison explains the difference between “Traceability” and “Authentication”. He points out that the term “Traceability” is sometimes known as “digital authentication”, where the term “Authentication” by itself is usually used to Continue reading Pharmaceutical Anti-Counterfeiting, A First-Rate New Resource